February 12, 2021 Participants in the CABANA trial who had stable heart failure—mostly with preserved ejection fraction—in addition to atrial fibrillation (AF) at baseline fared better when they underwent catheter ablation than when they were started on medical therapy alone, a detailed subgroup analysis shows. Those randomized to ablation had lower risks of mortality, the primary composite outcome of the trial (death, disabling stroke, serious bleeding, or cardiac arrest), and AF recurrence, as well as improved quality of life, according to researchers led by Douglas Packer, MD (Mayo Clinic Hospital—St. Marys Campus, Rochester, MN), principal investigator for the trial.